Steven Jon Russell - Jan 31, 2025 Form 4 Insider Report for Beta Bionics, Inc. (BBNX)

Role
Chief Medical Officer
Signature
/s/ Stephen Feider, Attorney-in-Fact
Stock symbol
BBNX
Transactions as of
Jan 31, 2025
Transactions value $
$0
Form type
4
Date filed
2/3/2025, 08:30 PM
Previous filing
Jan 29, 2025
Next filing
Mar 3, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBNX Employee Stock Option (right to buy) Award $0 +81.2K $0.00 81.2K Jan 31, 2025 Common Stock 81.2K $7.51 Direct F1, F2
transaction BBNX Employee Stock Option (right to buy) Award $0 +53.6K $0.00 53.6K Jan 31, 2025 Common Stock 53.6K $5.10 Direct F2, F3
transaction BBNX Employee Stock Option (right to buy) Award $0 +90.6K $0.00 90.6K Jan 31, 2025 Common Stock 90.6K $17.00 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth of the shares subject to this option shall vest one year after November 14, 2022, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof.
F2 Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock.
F3 The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.
F4 Vesting is monthly over a 48-month period starting January 29, 2025 in equal monthly amounts.